

6. Summary and Conclusion

Type 2 diabetes mellitus (T2DM) is a metabolic disorder of fuel homeostasis characterized by hyperglycemia and altered lipid metabolism caused by islet β cells being unable to secrete adequate insulin and insulin resistance. The elevated prevalence of this disease results in part from an increased rate of obesity in individuals with genetic predisposition for T2DM. Genetic studies have demonstrated that known variants account for less than 10% of the estimated overall genetic contribution to T2DM predisposition, suggesting that additional unidentified factors contribute to susceptibility of this disease. An important hypothesis for burdening of diabetes is called "developmental programming" or "fetal programming of diabetes". This concept assumes that, the maternal health challenges like malnutrition during gestation evoke a persistent physiological response in the offspring that may program those offspring for the development of diseases like diabetes.

The present work was aimed to study the effect of pre-gestational maternal protein malnutrition on the expression of Uncoupling Protein 2 (UCP2) and mitochondrial transcription factor-A (mtTFA) as modulators in the glucose sensing of the different organs (pancreas, liver, muscles and adipose tissues) of the first generation rat offspring.

In this study 50 local female Wistar rats (one month age) were divided into two experimental groups:

- Group I: Control group (C) consisting of 25 rats feed normal control diet (20% protein) for 3 months
- Group II: Low-protein group (LP) consisting of 25 rats feed an isocaloric low-protein diet (LP; 8% protein) for 3 months

Following mating with normal male rats, all pregnant female rats (control and Low-protein) were allowed to give birth naturally. The offspring were weaned to either control diet or high-caloric diet and followed up for 30 weeks. The following parameters were assayed; glucose, insulin, non-esterified fatty acids (NEFA) and lipid profile. The rats were dissected out to obtain pancreas, liver, muscle and adipose tissues for assessment of insulin receptor, phospho-insulin receptor (P-IR) and mtTFA and UCP2 gene expression

In the present study, maternal protein malnutrition appears to affect pregnancy outcome as it caused significant decrease in the number of pups per litter and pups weight.

Follow up of F1 offspring indicated that, the male and female offspring of LP mothers became over weight and post-natal feeding with HCD further increases weight gain. This indicated obesogenic behavior of the offspring. The offspring of malnourished mothers maintained under control diet showed normal glucose tolerance and insulin sensitivity while those maintained under high caloric diet showed age- dependant decline in glucose tolerance and insulin sensitivity which became significant from the 15th week of age especially in male. With age 30 week, mild hyperglycemia was detected in the male offspring of LP mothers (under HCD only) while in females no hyperglycemia was detected and IGT was aggravated.

The histopathological data indicated that, the pancreas offspring of LP mothers under HCD showed sign of inflammation crowded and increased activity of β -cells compared to control. Immunohistological results revealed that the offspring of LP mother showed decreased total β -cell mass while the individual β -cell area and mass are significantly increased especially in the male rats under HCD.

The observed shifts in glucose homeostasis were associated with changes in the peripheral sensing of glucose in muscle, liver and adipose tissues assayed at the insulin receptor level as insulin receptor and its active fraction; phospho-IR.

The observed abnormalities in glucose homeostasis in the offspring of LP mothers are associated with lipid profile disturbances and elevated NEFA. Also, the gene expression of mitochondrial transcription factor A and uncoupling protein 2 the main player in

6- Summary and conclusion

mitochondrial biogenesis and functions showed abnormal pattern in the offspring of LP mothers under HCD especially in the adipose tissues and liver .The expression of UCP2 appears to depend on the type of diets used especially in adipose tissues and liver.

From the results of the present study we can conclude that:

- 1- Pre-gestational and gestational low protein nutrition significantly decrease number of pups and pups weight
- 2- The offspring of protein malnourished mothers are at high risk for the development of T2DM as indicated by impaired glucose sensing, insulin resistance and hyperglycemia
- 3- Pre-gestational and gestational maternal protein malnutrition affects the offspring insulin sensitivity and glucose sensing parameters in the different peripheral tissues.
- 4- The post-natal diets differentially affect the studied parameters; as the control healthy balanced post-natal diets has no effect or even ameliorate the glucose sensing and insulin sensitivity in the offspring while high caloric post-natal feeding reverses the situation completely; as the offspring showed derangements in the glucose sensing (down regulation of insulin receptor and phospho-insulin receptor)
- 5- The offspring of LP mothers especially those feed HCD showed features of dyslipidemia and elevated non-esterified fatty acids
- 6- The same offspring showed disturbed pattern of gene expression of mitochondrial transcription factor A and uncoupling protein 2 which control mitochondrial biogenesis and functions
- 7- The male offspring of LP mothers appears to be more susceptible for development of T2DM than female offspring.

7-References

1. Jones PM, Persaud SJ. Islet Function and Insulin Secretion. In: Textbook of Diabetes. Holt RIG, Cockram CS, Flyvbjerg A, Goldstein RJ (eds). 4th Ed. Wiley Blackwell, USA. 2010, pp. 87 – 103.
2. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. *Proc Natl Acad Sci U S A* 2006; 103:2334–9.
3. Taylor TD, Noguchi H, Totoki Y, Toyoda A, Kuroki Y, Dewar K, et al. Human chromosome 11 DNA sequence and analysis including novel gene identification. *Nature* 2006; 440:497 – 500.
4. Melloul D, Marshak S, Cerasi E. Regulation of insulin gene transcription. *Diabetologia* 2002; 45:309 – 26.
5. Hutton JC. Insulin secretory granule biogenesis and the proinsulin processing endopeptidases. *Diabetologia* 1994; 37(Suppl 2): S48–S56.
6. Ashcroft SJ, Bunce J, Lowry M, Hansen SE, Hedekov CJ. The effect of sugars on (pro) insulin biosynthesis. *Biochem J* 1978; 174:517 – 26.
7. Hickey AJ, Bradley JW, Skea GL, Middleditch MJ, Buchanan CM, Phillips AR et al. Proteins associated with immunopurified granules from a model pancreatic islet beta - cell system: proteomic snapshot of an endocrine secretory granule. *J Proteome Res* 2009; 8: 178 – 186.
8. Dunn MF. Zinc – ligand interactions modulate assembly and stability of the insulin hexamer: a review. *Biometals* 2005; 18:295–303.
9. De Meyts P. Insulin and its receptor: structure, function and evolution. *Bioessays* 2004; 26(12):1351–62.
10. Frank BH, Pekar AH, Veros AJ. Insulin and Conformation in Solution. *Diabetes* 1972; 21(supp2):486-491.
11. Goldman J, Carpenter FH. Zinc binding, circular dichroism, and equilibrium sedimentation studies on insulin (bovine) and several of its derivatives. *Biochemistry* 1974; 13 (22): 4566–74.
12. Milthorpe BK, Nichol LW, Jeffrey PD. The polymerization pattern of zinc (II)-insulin at pH 7.0. *Biochim Biophys Acta* 1977; 495(2):195-202.
13. Fu Z, Gilbert ER, Liu D. Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes. *Curr Diabetes Rev* 2013; 9(1): 25–53.
14. Li G, Rungger - Brandle E, Just I, Jonas JC, Aktories K, Wollheim CB. Effect of disruption of actin filaments by *Clostridium botulinum* C2 toxin on insulin secretion in HIT - T15 cells and pancreatic islets. *Mol Biol Cell* 1994; 5:1199 – 1213.

7-References

15. Komatsu M, Takei M, Ishii H, Sato Y. Glucose-stimulated insulin secretion: A newer perspective. *J Diabetes Invest.* 2013; (doi: 10.1111/jdi.12094).
16. Wu X, Garvey WT. Insulin Action. In: *Textbook of Diabetes.* Holt RIG, Cockram CS, Flyvbjerg A, Goldstein RJ (eds). 4th Ed. Wiley Blackwell, USA. 2010, pp.104 – 25.
17. Saltiel AR, Pessin JE. Insulin signaling in microdomains of the plasma membrane. *Traffic* 2003; 4:711 - 16.
18. Chang L, Chiang S, Saltiel AR. Insulin signaling and the regulation of glucose transport. *Mol Med* 2004; 10: 65 - 71.
19. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. *Nature* 2001; 414:799 – 806.
20. Ciaraldi TP. Cellular Mechanisms of Insulin Action. In: *Principles of Diabetes Mellitus.* Poretsky L (ed). 2nd Ed. Springer. 2010, pp. 75 - 87.
21. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol-3 kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes: studies with a selective inhibitor wortmannin. *J Biol Chem* 1994; 269: 3568- 73.
22. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signaling pathways: insights into insulin action. *Nat Rev Mol Cell Biol* 2006; 7: 85 – 96.
23. Frame S, Cohen P. The renaissance of GSK3. *Nat Rev Mol Cell Biol* 2001; 2: 769 – 76.
24. Lee J, Kim M. The role of GSK3 in glucose homeostasis and the development of insulin resistance. *Diab Res Clin Pract* 2007; 77:49 – 57.
25. Fang X, Yu SX, Lu Y, Bast RC J, Woodgett JR, Mills GB.. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proc Natl Acad Sci* 2000; 97:11960 – 5.
26. Yki-Järvinen H. Insulin Resistance in Type 2 Diabetes. In: *Textbook of Diabetes.* Holt RIG, Cockram CS, Flyvbjerg A, Goldstein RJ (eds). 4th Ed. Wiley Blackwell, USA. 2010, pp. 174 – 90.
27. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. *Lancet* 2005; 365:1333 – 46.
28. American Diabetes Association. Standards of Medical Care in Diabetes. *Diabetes Care* 2014; 37(Suppl. 1): S14-S80.
29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2014; 37(Suppl. 1): S81–S90
30. Leu JP, Zonszein J. Diagnostic Criteria and Classification of Diabetes. In: *Principles of Diabetes Mellitus.* Poretsky L (ed). 2nd Ed. Springer. 2010, pp. 107 - 15.

7-References

31. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. *J Clin Endocrinol Metab* 2004; 89:447 – 52.
32. Ellard S, Beards F, Allen LI, Shepherd M, Ballantyne E, Harvey R, et al. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. *Diabetologia* 2000; 43:250 – 3.
33. Alberti KGM. The Classification and Diagnosis of Diabetes Mellitus. In: *Textbook of Diabetes*. Holt RIG, Cockram CS, Flyvbjerg A, Goldstein RJ (eds). 4th Ed. Wiley Blackwell, USA. 2010, pp.24 – 30.
34. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet* 2009; 373: 1773 – 9.
35. American Diabetes Association. Report of the expert committee on the diagnosis and the classification of diabetes mellitus. *Diabetes Care* 2009; 32: 62-7.
36. Saiger H, Machicao F, Fritsche A, Haring HU. Pathomechanisms of type 2 diabetes genes. *Endocrine Reviews* 2009; 30:557-85.
37. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. *Mol Cancer* 2003; 2: 2-4.
38. Luna B, Pharm D, Feinglos MN. Drug-induced hyperglycemia. *JAMA* 2001; 286:1945-8.
39. Forrest JM, Fiona MT, Margaret AB, Gary FS, Frank JM, Trevor TD, et al. Congenital rubella patients 60 years later. *MJA* 2002; 177: 664-7.
40. D’Annunzio G, Minuto N, D’Amato E, De Toni T, Lombardo F, Pasquali L, et al. Wolfram Syndrome (Diabetes insipidus, Diabetes, optic atrophy, and deafness). *Diab Care* 2008; 31: 1743-5.
41. International Expert Committee. International Expert Committee report on The role of the A1C assay in the diagnosis of diabetes. *Diab Care* 2009;32:1327–1334
42. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, (ed.). *Diabetes mellitus*. In: *Harrisons Principles of Internal Medicine*. McGraw-Hill. Europe 18th ed. 2011, pp. 1137-43.
43. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diab Res Clin Pract* 2010; 87: 4–14.
44. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes Estimates for the year 2000 and projections for 2030. *Diab Care* 2004; 27: 1047 – 53.
45. Colagiuri S. Diabetes: therapeutic options. *Diabetes Obes Metab* 2010; 12: 463–73.
46. Meas T. Fetal origins of insulin resistance and the metabolic syndrome: a key role for adipose tissue. *Diabetes Metab* 2010;36:11–20

7-References

47. Kanaka-Gantenbein C. Fetal origins of adult diabetes. *Ann New York Acad Sci* 2010; 1205(1):99–105.
48. Gluckman PD, Hanson MA, Spencer HG & Bateson P. Environmental influences during development and their later consequences for health and disease: implications for the interpretation of empirical studies. *Pro Biol Sci* 2005; 272: 671–7.
49. McMillen IC & Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. *Physiol Rev* 2005; 85: 571–633.
50. Barker DJ. Fetal origins of coronary heart disease. *BMJ* 1995; 311:171-4.
51. Phillips DI. Birth weight and the future development of diabetes. A review of the evidence. *Diab Care* 1998; 21 (Supplement 2): B150–B155.
52. Woodall SM, Johnston BM, Breier BH & Gluckman PD. Chronic maternal undernutrition in the rat leads to delayed postnatal growth and elevated blood pressure of offspring. *Ped Res* 1996; 40: 438–443.
53. Kwong WY, Wild AE, Roberts P, Willis AC & Fleming TP. Maternal undernutrition during the preimplantation period of rat development causes blastocyst abnormalities and programming of postnatal hypertension. *Develop* 2000; 127: 4195–4202.
54. Jansson T & Lambert GW. Effect of intrauterine growth restriction on blood pressure, glucose tolerance and sympathetic nervous system activity in the rat at 3–4 months of age. *J Hyperten* 1999; 17: 1239–1248.
55. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A & Seckl JR. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. *J Clin Invest* 1998; 101: 2174–81.
56. Jehn M, Brewis A. Paradoxical malnutrition in mother-child pairs: untangling the phenomenon of over- and under nutrition in underdeveloped economies. *Econ Hum Biol* 2009; 7:28–35.
57. Black RE, Allen LH, Bhutta ZA, Caulfield LE, Onis Mde, Ezzati M et al. Maternal and child undernutrition: global and regional exposures and health consequences. *The Lancet* 2008; 37:243–60.
58. Bratanova-Tochkova TK, Cheng H, Daniel S, Subhadra G, Liu YJ, Jennifer MM et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. *Diabetes* 2002; 51(Suppl 1): S83–S90.
59. Aizawa T, Komatsu M. Rab27a: A new face in beta cell metabolism-secretion coupling. *J Clin Invest* 2005; 115:227–30.
60. Brun T, Roche E, Assimacopoulos-Jeannet F, Corkey BE, Kim KH, Prentki M. Evidence for an anaplerotic/malonyl-CoA pathway in pancreatic β -cell nutrient signaling. *Diabetes* 1996; 45: 190–198.

7-References

61. Bateson P, Barker D, Clutton-Brock T, Deb D, D'Udine B, Foley RA et al. Developmental plasticity and human health. *Nature* 2004; 430:419–21.
62. Gluckman PD, Hanson MA. The developmental origins of the metabolic syndrome. *Tren Endocrinol Metab* 2004; 15:183–7.
63. Pike KC, Hanson MA, Godfrey KM. Developmental mismatch: consequences for later cardiorespiratory health. *B J Obst Gyn* 2008; 115:149-57.
64. Baydekar A, Yajnik CS, Fall CHD, Bapat S, Pandit AN, Deshpande V, et al. Insulin resistance syndrome in 8-year-old Indian children: small at birth, big at 8years, or both. *Diabetes* 1999; 48(12):2422–9.
65. Brenseke B, Prater MR, Bahamonde J, Gutierrez JC. Current Thoughts on Maternal Nutrition and Fetal Programming of the Metabolic Syndrome: a review. *J Pregn* 2013;doi/10.1155/368461
66. McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. *Physiol Re* 2005; 85(2):571–633.
67. Hofman PL, Cutfield WS, Robinson EM, Bergman RN, Menon RK, Sperling MA et al .Insulin resistance in short children with intrauterine growth retardation. *J Clin Endocrinol and Metab* 1997; 82(2):402–6.
68. Ong KKL, Ahmed ML, Dunger DB, Emmett PM, Preece MA. Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. *BMJ* 2000;320(7240):967–71.
69. Luo ZC, Fraser WD, Julien P, Deal CL, Audibert F, Smith GN et al. Tracing the origins of “fetal origins” of adult diseases: programming by oxidative stress. *Med Hypoth* 2006; 66:38–44.
70. Willcox JK, Ash SL and Catignani GL. Antioxidants and prevention of chronic disease. *Crit Rev Food Sci and Nutrit* 2004; 44(4):275–95.
71. Lenzen S. Oxidative stress: the vulnerable β -cell. *Bioch Soci Transact* 2008;36(3):343–47.
72. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arterioscl, Thromb, and Vasc Biol* 2004;24(5):816–23.
73. Fazzari MJ, Greally JM. Introduction to epigenomics and epigenome-wide analysis. *Meth Mol Biol* 2010; 620: 243–65.
74. Kim JK, Samaranyake M, Pradhan S. Epigenetic mechanisms in mammals. *Cell Mol Life Sci* 2009; 66: 596–612.
75. Crider KS, Yang TP, Berry RJ, and Bailey LB. Folate and DNA Methylation: A Review of Molecular Mechanisms and the Evidence for Folate’s Role. *American Society for Nutrition. Adv Nutr* 2012; 3: 21–38.

7-References

76. Gluckman PD, Hanson MA, Beedle AS. Non-genomic transgenerational inheritance of disease risk. *Bio Essays* 2007; 29(2):145–54.
77. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. *New Eng J Med* 2008; 359(1):6–73.
78. Portrait F, Teeuwiszen E, Deeg D. Early life undernutrition and chronic diseases at older ages: the effects of the Dutch famine on cardiovascular diseases and diabetes. *Soc Sci Med* 2011; 73(5):711–8.
79. Yajnik CS. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. *J Nutrit* 2004; 134(1):205–10.
80. Jiang X, Ma H, Wang Y, and Liu Y. Early Life Factors and Type 2 Diabetes Mellitus. A review. *J Diab Res* 2013; (doi: 10.1155/5082).
81. Brehm A, Krssak M, Schmid AI, Nowotny P, Waldhausl W, Roden M. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. *Diabetes* 2006; 55:136–140.
82. Frisard M, Ravussin E. Energy metabolism and oxidative stress: impact on the metabolic syndrome and the aging process. *Endocrine* 2006; 29:27–32.
83. Thundathil J, Filion F, Smith LC .Molecular control of mitochondrial function in preimplantation mouse embryos. *Mol Reprod Dev* 2005; 71: 405-13.
84. Aral C, Özer A. Mitochondrial DNA and cancer. *Marm Med J* 2007; 20(2):127-36.
85. Dimauro S, Schon EA. Mitochondrial respiratory-chain diseases. *N Eng J Med* 2003;348:2656–68
86. Rohan TE, Wong LJ, Wang T, Haines J, Kabat GC. Do Alterations in Mitochondrial DNA Play a Role in Breast Carcinogenesis? *J of Oncol* 2010; 2010: 1–11.
87. Beal MF. Mitochondria take center stage in aging and neurodegeneration. *Ann Neurol* 2005 ;58:495–505
88. Dimauro S. Mitochondrial medicine. *Biochim Biophys Acta* 2004; 1659: 107-114.
89. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Oxford: Oxford University Press, 2007.
90. Pradelli LA, Be ´ne ´teau M, Ricci JE. Mitochondrial control of caspase-dependent and independent cell death. *Cell Mol Life Sci* 2010; 67:1589–97.
91. Benard G, Rossignol R. Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. *Antioxid Redox Sign* 2008; 10:1313-42.
92. Krauss S, Zhang C, Lowell BB. The mitochondrial uncoupling-protein homologues. *Nat Rev Mol Cell Biol*2005; 6(3):248–61.

7-References

93. Lanza IR, Nair KS. Mitochondrial function as a determinant of life span. *Pflügers Archiv- Eur J Physiol* 2010; 459: 277–89.
94. West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. *Nat Rev Immunol* 2011; 11:389-402.
95. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. *N Eng J Med* 2009; 361: 1570–83.
96. Gupta S, Kass GE, Szegezdi E, Joseph B. The mitochondrial death pathway: a promising therapeutic target in Diseases. *J Cell Mol Med* 2009; 13:1004–33
97. Igney F H, Krammer PH. Death and anti-death tumour resistance to apoptosis. *Nat Rev Cancer* 2002; 2: 277-88.
98. Ott M, Zhivotovsky B, Orrenius S. Role of cardiolipin in cytochrome c release from mitochondria. *Cell Death Different* 2007; 14:1243-7.
99. Ow YP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. *Nat Rev Mol Cell Biol* 2008; 9:532–42.
100. Cande C, Cohen I, Daugas E, Ravagnan L, Larochette N, Zamzami N, Kroemer G. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. *Biochimie* 2002; 84:215–22.
101. Andreas W, Wollheim CB. Minireview: Implication of mitochondria in insulin secretion and action. *Endocrinol* 2006; 147:2643–9.
102. Matschinsky FM. Regulation of pancreatic β -cell glucokinase: from basics to therapeutics. *Diabetes* 2002; 51:S394–S404
103. Pebay-Peyroula E, Dahout C, Kahn R, Trezeguet V, Lauquin GM, Brandolin G. Structure of mitochondrial ADP/ATP carrier complex with carboxyatractyloside. *Nature* 2003; 426: 39–44.
104. Deeney JT, Prentki M, Corkey BE. Metabolic (ATP) control of beta-cell function. *Semi Cell Dev Biol* 2000; 11:267-75.
105. Davis WL, Plaza SM. Mitochondrial factors in the pathogenesis of diabetes: A hypothesis for treatment. *Altern Med Rev* 2002; 7:94-111
106. Wanrooij S, Falkenberg M. The human mitochondrial replication fork in health and disease. *Bioch Bioph Acta* 2010; 1797:1378–88.
107. Dimauro S. Mitochondrial DNA medicine. *Biosci Rep* 2007;27:5–9
108. Taanman JW. The mitochondrial genome: structure, transcription, translation and replication. *Biochem Biophys Acta* 1999; 1410:103–23.
109. Singhal N, Gupta BS, Saigal R, Makkar J, Mathur R. Mitochondrial diseases: an overview of genetics, pathogenesis, clinical features and an approach to treatment. *J of Postgrad Med* 2000; 46:224-30.

7-References

110. Lloyd RE , Lee JH, Alberio R, Bowles EJ, Ramalho-Santos J, Campbell KHS, et al. Aberrant nucleo-cytoplasmic cross-talk results in donor cell mtDNA persistence in cloned embryos. *Genet* 2006; 172: 2515–27.
111. Takamatsu C, Umeda S, Ohsato T, Ohno T, Abe Y, Fukuoh A, et al. Regulation of mitochondrial D-loops by transcription factor A and single-stranded DNA-binding protein. *EMBO Rep* 2002; 18:451–56.
112. Dimauro S, Schon EA. Mitochondrial disorders in the nervous system. *Ann Rev Neurosci* 2008; 31: 91-123.
113. Kutik S, Guiard B, Meyer H, Wiedemann N, Pfanner N. Cooperation of translocase complexes in mitochondrial protein import. *J Cell Biol* 2007; 179:585–91.
114. Reyes A, Mezzina M, Gadaleta G. Human mitochondrial transcription factor A (mtTFA): gene structure and characterization of related pseudogenes. *Gene* 2002; 291:223–32.
115. Dong X, Ghoshal K, Majumder S, Yadav SP, Jacob ST. Mitochondrial transcription factor A and its downstream targets are up-regulated in a rat hepatoma. *J of Biol Chem* 2002; 277: 43309–18.
116. Chandrika C, Scott M, Bayne A V, Peter S, Jingyan T, Nadja C, et al. The mitochondrial transcription factor A functions in mitochondrial base excision repair. *DNA Rep* 2010; 9:1080–9.
117. Dairaghi DJ, Shadel GS, Clayton DA. Addition of a 29 residue carboxyl-terminal tail converts a simple HMG box-containing protein into a transcriptional activator. *J Mol Biol* 1995; 249:11–28.
118. Spikings EC, Alderson J, John JCS. Transmission of mitochondrial DNA following assisted reproduction and nuclear transfer. *Hum Reprod* 2006; 12: 401–15.
119. Falkenberg M, Gaspari M, Rantanen A, Trifunovic A, Larsson NG, Gustafsson CM. Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. *Nature Genet* 2002; 31: 289–94.
120. Benoit R G, Andreas W, Mathurin B , Chunhua D, Alvin CP, Julie K, et al. PDX1 deficiency causes mitochondrial dysfunction and defective insulin secretion through TFAM suppression. *Cell Metab* 2009; 10:110-8.
121. Li N, Stojanovski S and Maechler P. Mitochondrial Hormesis in Pancreatic β Cells: Does Uncoupling Protein 2 Play a Role. A review. *Oxid Med Cell Long* 2012; (doi: 10.1155/740849).
122. Aquila H, Link TA, Klingenberg M. The uncoupling protein from brown fat mitochondria is related to the mitochondrial ADP/ATP carrier. Analysis of sequence homologies and of folding of the protein in the membrane. *EMBO J* 1985; 4: 2369–76.
123. Liu J, Li J, Li W, Wang C. The Role of Uncoupling Proteins in Diabetes Mellitus. A

7-References

- review. *J Diab Res* 2013; (doi: 10.1155/585897).
124. Ledesma A, Lacoba MG, Rial E. The mitochondrial uncoupling proteins. *Geno biol* 2002; 3(12): 3015.1-3015.9.
 125. Diano S, Horvath TL. Mitochondrial uncoupling protein2 (UCP2) in glucose and lipid metabolism. *Tren Mol Med* 2012; 18(1):pp.52–8.
 126. Emre Y, T Nübel. Uncoupling protein UCP2: when mitochondrial activity meets immunity. *FEBS Lett* 2010; 584(8):1437–42.
 127. Mehta SL, Li PA. Neuroprotective role of mitochondrial uncoupling protein 2 in cerebral stroke. *J Cereb Blood Flow Metab* 2009; 29(6):1069–78.
 128. Ricquier D, Bouillaud F. The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. *Biochem J* 2000;345: 161-79
 129. Ramsden DB, Ho PW, Ho JW, Liu HF, So DH, Tse HML et al. Human neuronal uncoupling proteins 4 and 5 (UCP4 and UCP5): structural properties, regulation, and physiological role in protection against oxidative stress and mitochondrial dysfunction. *Brain Behav* 2012;2(4):468–78.
 130. Mailloux RJ, Harper M. Uncoupling proteins and the control of mitochondrial reactive oxygen species production. *Free Rad Biol Med* 2011; 51(6):1106–15.
 131. Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. *Nat Genet* 1997; 15(3):269-72.
 132. Souza BM, Assmann TS, Kliemann LM, Gross JL, Canani LH, Crispim D. The role of uncoupling protein 2 (UCP2) on the development of type 2 diabetes mellitus and its chronic complications. *Arg Bras Endocrinol metabol* 2011; 55(4):239-48.
 133. Fisler J, Warden CH. Uncoupling proteins, dietary fat and the metabolic syndrome. *Nutr Metab* 2006; 3:38.
 134. Azzu V, Jastroch M, Divakaruni AS, Brand MD. The regulation and turnover of mitochondrial uncoupling proteins. *Biochim Biophys Acta* 2010; 1797(6-7):785-91.
 135. Boss O, Samec S, Paoloni-Giacobino A, Rossier C, Dulloo A, Seydoux J, et al. Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue specific expression. *FEBS Lett* 1997; 408:39–42.
 136. Mao W, Yu XX, Zhong A, Li W, Brush J, Sherwood SW et al. UCP4, a novel brain-specific mitochondrial protein that reduces membrane potential in mammalian cells. *FEBS Lett* 1999; 443: 326–30.
 137. Sanchis D, Fleury C, Chomiki N, Gubern M, Huang Q, Never-ova M et al. BMCP1, a novel mitochondrial carrier with high expression in the central nervous system of humans and rodents and respiration uncoupling activity in recombinant yeast. *J Biol Chem* 1998; 273:34611–5.

7-References

138. Bouillaud F, Ricquier D, Mory G, Thibault J. Increased level of mRNA for the uncoupling protein in brown adipose tissue of rats during thermogenesis induced by cold exposure or norepinephrine infusion. *J Biol Chem* 1984; 259:11583–6.
139. Medvedev AV, Robidoux J, Bai X, Cao W, Floering LM, Daniel KW et al. Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. *J Biol Chem* 2002; 277: 42639–44.
140. Oberkofler H, Klein K, Felder TK, Krempler F, Patsch W. Role of peroxisome proliferator-activated receptor-gamma co-activator-1 alpha in the transcriptional regulation of the human uncoupling protein 2 gene in INS-1E cells. *Endocrinol* 2006; 147:966–76.
141. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. *PLoS Biol* 2006; 4: e31.
142. Hurtaud C, Gelly C, Bouillaud F, and Levi-Meyrueis C. Translation control of UCP2 synthesis by the upstream open reading frame. *Cell. Mol. Life Sci.* 2006; 63: 1780–9.
143. Hurtaud C, Gelly C, Chen Z, Le 'vi-Meyrueis C, Bouillaud F. Glutamine stimulates translation of uncoupling protein 2mRNA. *Cell Mol Life Sci* 2007;64:1853–60.
144. Rousset S, Mozo J, Dujardin G, Emre Y, Masscheleyn S, Ricquier D et al. UCP2 is a mitochondrial Transporter with an unusual, very short half-life. *FEBS Lett* 2007; 581: 479–82.
145. Ježek P, Olejář T, Smolková K, Ježek J, Dlasková A, Plecítá-Lavátá L et al. Antioxidant and Regulatory Role of Mitochondrial Uncoupling Protein UCP2 in Pancreatic β -cells. A review. *Physiol Res* 2014; 63 (Suppl. 1): S73-S91.
146. Pecqueur C, Alves-Guerra C, Ricquier D, Bouillaud F. UCP2, A Metabolic Sensor Coupling Glucose Oxidation to Mitochondrial Metabolism. *IUBMB Life* 2009; 61(7): 762–7.
147. Nedergaard J, Cannon B. The 'novel' 'uncoupling' proteins UCP2 and UCP3: what do they really do? Pros and cons for suggested functions. *Exp Physiol* 2003; 88: 65–84.
148. Parton LE, Ye CP, Coppari R, Enriori PJ, Choi B, Zhang CY et al. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. *Nature* 2007; 449: 228–32.
149. Weigle DS, Selfridge LE, Schwartz MW, Seeley RJ, Cummings DE, Havel PJ et al. Elevated free fatty acids induce uncoupling protein 3 expression in muscle: a potential explanation for the effect of fasting. *Diabetes* 1998; 47:298–302.
150. Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D and Warden CH. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. *Nat Genet* 1997; 15:269–72.
151. Brun S, Carmona MC, Mampel T, Viñas O, Giralt M, Iglesias R et al. Activators of

7-References

- peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake dependent activation of uncoupling protein-3 gene expression at birth. *Diabetes* 1999; 48:1217–22.
152. Curi R, Newsholme P, Newsholme EA. Metabolism of pyruvate by isolated rat mesenteric lymphocytes, lymphocyte mitochondria and isolated mouse macrophages. *Biochem J* 1988; 250: 383–8.
 153. Faggioni R, Shigenaga J, Moser A, Feingold KR, Grunfeld C. Induction of UCP2 gene expression by LPS: a potential mechanism for increased thermogenesis during infection. *Biochem Biophys Res Commun* 1998; 244:75–8.
 154. Hidaka S, Yoshimatsu H, Kakuma T, Sakino H, Kondou S, Hanada R et al. Tissue-specific expression of the uncoupling protein family in streptozotocin-induced diabetic rats. *Proc Soc Exp Biol Med* 2001; 224:172–7.
 155. Reilly JM, Thompson MP. Dietary fatty acids upregulate the expression of UCP2 in 3T3-L1 preadipocytes. *Biochem Biophys Res Commun* 2000; 277:541–5.
 156. Chevillotte E, Rieusset J, Roques M, Desage M, Vidal H. The regulation of uncoupling protein-2 gene expression by omega-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome proliferator-activated receptor beta. *J Biol Chem* 2001; 276:10853–60.
 157. Camirand A, Marie V, Rabelo R, Silva JE. Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle. *Endocrinol* 1998; 139: 428–31.
 158. Fukuda H, Hirakawa T, Iritani N. Nutritional and hormonal regulation of uncoupling protein gene expression in rat adipocytes. *J Nutr Sci Vitaminol* 2007; 53: 426–31.
 159. Yonezawa T, Sanosaka M, Haga S, Kobayashi Y, Katoh K, Obara Y. Regulation of uncoupling protein 2 expression by long-chain fatty acids and hormones in bovine mammary epithelial cells. *Biochem Biophys Res Commun* 2008; 375:280–5.
 160. Yonezawa T, Kurata R, Hosomichi K, Kono A, Kimura M, Inoko H. Nutritional and Hormonal Regulation of Uncoupling Protein 2. *IUBMB Life* 2009; 61(12):1123–31.
 161. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell* 1997; 89:331–40.
 162. Pedersen SB, Nyholm B, Kristensen K, Nielsen MF, Schmitz O, Richelsen B. Increased adiposity and reduced adipose tissue mRNA expression of uncoupling protein-2 in first-degree relatives of type 2 diabetic patients: evidence for insulin stimulation of UCP-2 and UCP-3 gene expression in adipose tissue. *Diab Obes Metab* 2005; 7:98–105.
 163. Pedersen SB, Lund S, Buhl ES, Richelsen B. Insulin and contraction directly stimulate UCP2 and UCP3 mRNA expression in rat skeletal muscle in vitro. *Biochem Biophys Res Commun* 2001; 283:19–25.

7-References

164. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994; 372: 425–32.
165. Minokoshi Y, Kim Y-B, Peroni OD, Fryer LGD, Müller C, Carling D et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. *Nature* 2002; 415: 339–43.
166. Friedman JM. The alphabet of weight control. *Nature* 1997; 385: 119–20.
167. Guerre-Millo M. Adiponectin: an update. *Diabetes Metab* 2008; 34: 12–8.
168. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. *Nat Med* 2007; 13: 332–39.
169. Wells T. Ghrelin – defender of fat. *Prog Lipid Res* 2009; 48: 257–74.
170. Vatamaniuk MZ, Gupta RK, Lantz KA, Doliba NM, Matschinsky FM, Kaestner KH. Foxal-deficient mice exhibit impaired insulin secretion due to uncoupled oxidative phosphorylation. *Diabetes* 2006; 55: 2730–6.
171. Dahri S, Snoeck A, Reusens-Billen B, Remacle C, Hoet JJ. Islet function in offspring of mothers on low-protein diet during gestation. *Diabetes* 1991; 40 (Suppl 2): 115–20.
172. Burtis C, Ashwood ER, Bruns DE. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*. 4th edition. Elsevier Saunders Company. St Louis. 2006, pp. 902-5 (glucose), 938-40 (triglycerides), 945-7 (cholesterol), 952-5 (HDL & LDL-cholesterol)
173. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance. *Diabetes*. 2000; 76: 2094–101
174. Caumo A, Perseghin G, Brunani A, Luzi L. New insights on the simultaneous assessment of insulin sensitivity and Beta-cell function with the HOMA2 method. *Diab Care* 2006; 29: 2733-4.
175. Mulder C, Schouten JA, Popp-Snijders. Determination of free fatty Acids: A Comparative Study of the Enzymatic Versus the Gas Chromatography and the Colorimetric Method. *J Clin Chem Clin Biochem* 1983, 21: 823-7
176. Zhang YL, Tam M, Kirincich S, Wan ZK, Wilson D, Komar C. An enzyme-linked immunosorbent assay to measure insulin receptor dephosphorylation by PTP1B. *Analy Biochem* 2007; 365: 174–84.
177. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with Folin-phenol reagent. *J Biol Chem* 1951; 193: 265-70.
178. Peirson SN, Butler JN. RNA extraction from mammalian tissues. In: *Methods in Molecular Biology*, vol.: *Circadian Rhythms: Methods and Protocols* Edited by: E. Rosato Humana Press Inc, Totowa, NJ USA 2008; 362: 315-327.

7-References

179. Piantadosi CA, Suliman HB. Mitochondrial transcription factor A induction by redox activation of nuclear respiratory factor 1. *J Biol Chem* 2006; 281:324-33.
180. Berraondo B, Marti A, Duncan JS, Trayhurn P, Martinez JA. Up-regulation of muscle UCP2 gene expression by a new β -adrenoceptor agonist, trectadrine, in obese (cafeteria) rodents, but down regulation in lean animals. *Int J Obes* 2000; 24:156-63.
181. Kiernan AJ. Dyes. In: *Histological and histochemical methods: Theory and practical*. 4th edition. Scion publishing LTD. Malta 2008.
182. Montanya E, Téllez N. Pancreatic Remodeling: Beta-Cell Apoptosis, Proliferation and Neogenesis, and the Measurement of Beta-Cell Mass and of Individual Beta-Cell Size. In: *methods in molecular biology. Type 2 Diabetes, Methods and Protocols*. Stocker C (ed). Humana Press, UK 2009: pp. 142 -144.
183. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat Genet* 2012; 44(9):981–90.
184. Sandovici I, Hammerle CM, Ozanne SE, Constância M. Developmental and environmental epigenetic programming of the endocrine pancreas: consequences for type 2 diabetes. *Cell Mol Life Sci* 2013; 70(9):1575–95.
185. Zambrano E, Martinez-Samayoa PM, Bautista CJ, Deas M, Guillen L, Rodriguez-Gonzalez GL et al. Sex differences in transgenerational alterations of growth and metabolism in progeny (F2) of female offspring (F1) of rats fed a low protein diet during pregnancy and lactation. *J Physiol* 2005;566: 225–36.
186. Pinney SE, Simmons RA. Metabolic programming, epigenetics, and gestational diabetes mellitus. *Curr Diab Rep*. 2012;12(1):67–74.
187. Rodríguez-Trejo1 A, Ortiz-López MG, Zambrano E, Granados-Silvestre MÁ, Méndez C, Blondeau B et al. Developmental programming of neonatal pancreatic β -cells by a maternal low-protein diet in rats involves a switch from proliferation to differentiation. *Am J Physiol Endocrinol Metab* 2012;302(11): E1431-E1439
188. Thompson LP, Al-Hasan Y. Impact of Oxidative Stress in Fetal Programming. A review. *J Preg* 2012; doi:10.1155/582748
189. Kamel MA. Prenatal Effects of Different Intra-Uterine Milieus on Fetal Glucose Sensing Mechanisms during Gestation in Rats. *J Diab Metab* 2012; 3:181.
190. Leroy J, Valckx S, Sturmey R, Bossaert P, Van Hoeck V, Bols P. Maternal metabolic health and oocyte quality: the role of the intrafollicular environment. *Anim Reprod* 2012; 9(4):777–88.
191. Snoeck A, Remacle C, Reusens B, Hoet J. Effect of a low protein diet during pregnancy on the fetal rat endocrine pancreas. *Neonatology* 1990;57(2):107–18

7-References

192. Drake AJ, Reynolds RM. Impact of maternal obesity on offspring obesity and cardiometabolic disease risk. *Reproduction* 2010; 140(3):387–98.
193. Isganaitis E, Jimenez-Chillaron J, Woo M, Chow A, DeCoste J, Vokes M, et al. Accelerated postnatal growth increases lipogenic gene expression and adipocyte size in low-birth weight mice. *Diabetes* 2009; 58(5):1192–200.
194. Desai M, Byrne CD, Meeran K, Martenz ND, Bloom SR. Regulation of hepatic enzymes and insulin levels in offspring of rat dams fed a reduced-protein diet. *Am J Physiol* 1997; 273: G899–G904.
195. Langley-Evans SC. Developmental programming of health and disease. *Proc Nutr Soc* 2006; 65: 97–105.
196. Döring F, Lüersen K, Schmelzer C, Hennig S, Lang IS, Görs S, et al. Influence of maternal low protein diet during pregnancy on hepatic gene expression signature in juvenile female porcine offspring. *Mol Nutr Food Res* 2013;57: 277–90
197. Coupe B, Grit I, Darmaun D, Parnet P. The timing of “catch-up growth” affects metabolism and appetite regulation in male rats born with intrauterine growth restriction. *Am J Physiol Regul Integr Comp Physiol* 2009; 297:R813–824.
198. Holness MJ, Langdown ML, Sugden MC. Early-life programming of susceptibility to dysregulation of glucose metabolism and the development of Type 2 diabetes mellitus. *Biochem J* 2000; 349(3): 657–65.
199. Fernandez-Twinn DS, Ozanne SE. Early life nutrition and metabolic programming. *Ann N Y Acad Sci*. 2010; 1212:78–96.
200. Dahri S, Snoeck A, Reusens-Billen B, Remacle C, Hoet JJ. Islet function in offspring of mothers on low-protein diet during gestation. *Diabetes* 1991; 40(suppl 2):115–120.
201. Chintinne M, Stangé G, Denys B, In 't Veld P, Hellemans K, Pipeleers-Marichal M et al. Contribution of postnatally formed small beta cell aggregates to functional beta cell mass in adult rat pancreas. *Diabetologia* 2010; 53: 2380–8.
202. Zambrano E1, Bautista CJ, Deás M, Martínez-Samayoá PM, González-Zamorano M, Ledesma H et al. A low maternal protein diet during pregnancy and lactation has sex- and window of exposure-specific effects on offspring growth and food intake, glucose metabolism and serum leptin in the rat. *J Physiol* 2006;571: 221–30.
203. Vijayaraghavan K. Treatment of dyslipidemia in patients with type 2 diabetes. *Lipids in Health and Dis* 2010; 9:144–55
204. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. *Curr Opin Lipidol* 2006; 17:238–46.
205. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2

7-References

- diabetes. *Diabetes Obes Metab* 2003; 5(1):S19-S27.
206. Mlinar B, Marc J, Janež A, Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. *Clin Chim Acta* 2007; 375(1): 20-35.
207. Turner N, Cooney GJ, Kraegen EW, Bruce CR. Fatty acid metabolism, energy expenditure and insulin resistance in muscle. Review. *J Endocrinol* 2014; 220: T61–T79.
208. Kasuga M, Kahn CR, Hedo JA, Van Obberghen E, Yamada KM. Insulin-induced receptor loss in cultured human lymphocytes is due to accelerated receptor degradation. *Proc Nat Acad Sci* 1981;78(11):6917– 21.
209. Puig O, Tjian R. Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. *Gene Develop* 2005;19(20):2435–46.
210. Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. *Mol Cell* 2000; 6(6):1401–12.
211. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Mol Cell* 2000; 6(1):87–97.
212. Emanuelli B, Vienberg SG, Smyth G, Cheng C, Stanford KI, Arumugam M et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. *J Clin Invest* 2014;124(2):515–27
213. Petry CJ, Dorling MW, Pawlak DB, Ozanne SE, Hales CN. Diabetes in old rat dams fed a reduced protein diet. *Int J Diabetes Res* 2001; 2:139–43.
214. Medina-Gómez G. Mitochondria and endocrine function of adipose tissue. *Best Pract Res Clinl Endocrinol Metab* 2012;26:791-804
215. Burgueno AL, Cabrerizo R, Gonzales Mansilla N, Sookoian S, Pirola CJ. Maternal high-fat intake during pregnancy programs metabolic-syndrome related phenotypes through liver mitochondrial DNA copy number and transcriptional activity of liver PPARGC1A. *J Nutr Biochem* 2013; 24: 6–13.
216. Theys N, Bouckenooghe T, Ahn MT, Remacle C, Reusens B. Maternal low-protein diet alters pancreatic islet mitochondrial function in a sex-specific manner in the adult rat. *Am J Physiol Regul Integr Comp Physiol* 2009; 297: R1516–1525.
217. Selak MA, Storey BT, Peterside I, Simmons RA. Impaired oxidative phosphorylation in skeletal muscle of ntrauterine growth-retarded rats. *Am J Physiol Endocrinol Metab* 2003; 285: E130–7.
218. Krebs M, Roden M. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. *Diab Obes Metab* 2005; 7(6):621–32.

7-References

219. Park KS, Kim SK, Kim MS, Cho EY, Lee JH, Lee K-U, et al. Fetal and early postnatal protein malnutrition cause long-term changes in rat liver and muscle mitochondria. *J Nutr* 2003; 133(10):3085–90.
220. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. *Cell* 2012; 148:852–71.
221. Wiederkehr A, Wollheim CB. Implication of mitochondria in insulin secretion and action. Minireview. *Endocrinol* 2006; 147:2643–9.
222. J Kim, Wei Y, Sowers JR. Role of Mitochondrial Dysfunction in Insulin Resistance. *Circ Res* 2008;102:401-14

٨- الملخص العربي

داء السكري من النوع الثاني (T2DM) هو اضطراب التمثيل الغذائي لتوازن الطاقة ويتميز بارتفاع السكر في الدم واضطراب التمثيل الغذائي للدهون وذلك ربما يكون بسبب فشل خلايا البنكرياس من نوع بيتا (β) في إفراز الأنسولين الكافي وأيضاً مقاومة الأنسولين. يرجع ارتفاع نسبة الإصابة لهذا المرض نتيجة لزيادة في نسبة السمنة لدى الأفراد مع استعداد وراثي للنوع الثاني من السكري T2DM. ظهرت نظرية هامة قد تساهم في الإصابة بالسكري وهي "البرمجة التنموية" أو "البرمجة الجينية لمرض السكري".

ويهدف هذا العمل إلى دراسة التعبير الجيني لعامل النسخ الميتوكوندري-أ و البروتينات الفاصلة ٢ باعتبارها وسائل لإستشعار الجلوكوز في الأعضاء المختلفة و ذلك في الجيل الأول من نسل الجرذان التي تعرضت لسوء التغذية (نقص البروتين) أثناء الحمل والرضاعة .

تمت الدراسة علي ٥٠ من إناث الجرذان (عمر شهر) تم تقسيمها الى:
 المجموعة الأولى: اشتملت علي ٢٥ من اناث الجرذان تم تغذيتها بطعام متوازن عادي (بروتين ٢٠٪) لمدة ٣ أشهر.
 • المجموعة الثانية: مجموعة منخفض البروتين، اشتملت علي ٢٥ من اناث الجرذان التي تتغذى على نظام غذائي منخفض البروتين (بروتين ٨٪) لمدة ٣ أشهر.

بعد التزاوج و الولادة تم فطام النسل على إما نظام غذائي متوازن أو عالي السعرات الحرارية ومتابعتها لمدة ٣٠ أسبوع. أظهرت نتائج ان سوء تغذية الأمهات بالبروتين أثناء الحمل و الرضاعة قد أثر على ناتج الحمل حيث انه تسبب في انخفاض ملحوظا في عدد الجراء و كذلك وزنها و ذلك بالمقارنة مع المجموعة الضابطة. و متابعة الجيل الأول من النسل أشارت النتائج إلى زيادة وزن الجراء في كل من الذكور والإناث من نسل الأمهات سيئة التغذية خاصة التي تم تغذيتها بعد الولادة بنظام غذائي عالي السعرات. وهذا دليل على احتمالية حدوث سمنة في هذه المجموعة.

أيضا أظهرت النتائج أن نسل الأمهات سيئة التغذية و التي تغذت على النظام الغذائي العادي بعد الفطام على تكون قادرة علي تحمل الجلوكوز وحساسية الأنسولين بشكل طبيعي في حين أن النسل الذين تم وضعهم على نظام غذائي عالي السعرات الحرارية أظهرت انخفاضا ملحوظا في تحمل الجلوكوز والحساسية للأنسولين مع التقدم بالسن والذي بدا واضحا من الأسبوع ١٥ من العمر خاصة في الذكور. مع التقدم في السن حتى الأسبوع ٣٠ تم اكتشاف زيادة متوسطة في مستوى السكر بالدم في الذكور من الأمهات سيئة التغذية (تحت نظام غذائي عالي السعرات الحرارية فقط) بينما في الإناث لم يتم اكتشاف ارتفاع السكر في الدم مع تقادم خلال حمل الجلوكوز.

وأشارت نتائج الفحص المناعي لبنكرياس نسل الأمهات سيئة التغذية تحت نظام غذائي عالي السعرات الحرارية أظهر علامة على التهاب خلايا بيتا مقارنة مع المجموعة الضابطة. ارتبطت التغيرات الملحوظة في توازن الجلوكوز مع التغيرات في عوامل استشعار الجلوكوز الطرفية في العضلات والكبد والأنسجة الدهنية وذلك عن طريق تعيين مستوى مستقبلات الأنسولين و مستقبلات الأنسولين النشطة (Phospho-IR). صاحبت التغيرات التي لوحظت في توازن الجلوكوز في نسل الأمهات سيئة التغذية اضطرابات في مستوى الدهون وارتفاع في الأحماض الدهنية (NEFA) بالدم. أيضا أظهر التعبير الجيني لعامل النسخ الميتوكوندري-أ و البروتينات الفاصلة ٢ و هما عاملان رئيسيان في تخليق و وظيفة الميتوكوندريا نمط غير طبيعي في نسل الأمهات سيئة التغذية تحت نظام غذائي عالي السعرات الحرارية خاصة في الأنسجة الدهنية والكبد مما يظهر اعتماد التعبير الجيني بهما على نوع الأنظمة الغذائية المستخدمة وخاصة في الأنسجة الدهنية والكبد.

من نتائج هذه الدراسة قد استنتجنا ما يلي:

١. سوء التغذية بالبروتين في مرحلة ما قبل الحمل والحمل يقلل بشكل ملحوظ عدد ووزن الجراء.

٢. نسل الأمهات سيئة التغذية بالبروتين هم عرضة لحدوث مرض السكري من النوع الثاني كما دل على ذلك ضعف استشعار الجلوكوز ومقاومة الأنسولين وارتفاع السكر في الدم.
٣. سوء التغذية بالبروتين الأمهات ما قبل الحمل والحمل يؤثر على حساسية الأنسولين وعوامل استشعار الجلوكوز في الأنسجة الطرفية المختلفة في نسلهن.
٤. النظام الغذائي بعد الولادة يؤثر بشكل متميز على المعاملات التي تم دراستها حيث أن التغذية بالوجبات الغذائية الصحية المتوازنة بعد الولادة ليس له تأثير بل حَسَّنَ من استشعار الجلوكوز وحساسية الأنسولين في هذه الذرية على عكس التغذية عالية السعرات بعد الولادة تماما حيث أظهر خلافا في استشعار الجلوكوز (إنخفاض مستقبلات الأنسولين ومستقبلات الأنسولين الفوسفورية).
٥. نسل الأمهات سيئة التغذية بالبروتين خاصة التي تغذت على نظام غذائي عالي السعرات أظرت زيادة في الدهون بالدم وارتفاع في الأحماض الدهنية .
٦. أظهرت نفس الذرية اضطراب في التعبير الجيني لكل من عامل النسخ الميتوكونديري-أ و البروتينات الفاصلة (٢) و التي تتحكم في البناء الحيوي للميتوكونديريا ووظائفها.
٧. الذكور من نسل الأمهات سيئة التغذية يبدو أنهم أكثر عرضة لتطور السكري من النوع الثاني من الإناث.

obeykandi.com

بسم الله الرحمن الرحيم

دراسة تأثير سوء التغذية في الأمهات على التعبير الجيني
لكل من جين البروتينات الفاصلة (٢) و جين عامل النسخ
الميتوكوندورى (أ) في الأنسجة المختلفة للجيل الاول من

نسل الجرذان

رسالة

مقدمة إلى معهد البحوث الطبية

جامعة الإسكندرية

إيفاءً جزئياً للحصول على

درجة الدكتوراة

في

الكيمياء الحيوية

من

محمود صلاح محمد بدر

بكالوريوس علوم- كيمياء حيوية

كلية العلوم

جامعة الإسكندرية – ١٩٩٦

ماجستير كيمياء طبية تطبيقية

معهد البحوث الطبية

جامعة الإسكندرية 2009

قسم الكيمياء الحيوية

معهد البحوث الطبية

جامعة الإسكندرية

٢٠١٤